Tanushree Samanta

· In AbbVie IO group, I am involved in establishing MOA and target validation of immune-oncology assets. Developed and designed experiments to identify new targets

· Involved with number of internal very novel targets; implementation, planning and execution of key set of experiments.

· Worked closely with translational team, proteomics team, assay development team for screening, implementation of crucial fundamental assays.

· Lead phospho-proteomics efforts with proteomics group for one of Abbvie assets to identify pathways, ligand for the novel IO target.

· Working cross functionally with translational team by providing essential input and data to ensure implementation of a biomarker plan.

· Collaborate with in vivo Pharmacology team to design and implementation of in vivo assay to find out cellular level deeper understanding of effect of a drug in murine animal model

· Proficiency and understanding in a wide range of laboratory techniques- cell culture, cell transfection, Immunoassays (ELISA, MLR, single cell RNA sequencing, bulk RNA seq, cytotoxicity assay, MSD, Luminex etc), cellular/functional ex-vivo assays.

· Multicolor flow cytometry – design and efficiently analyze data using different software’s, and present data in timely manner crucial for decision making.

· Supported the project team by providing scientific reports, clear and concise summaries of the data to come to drive the key projects towards right direction.

· Evaluate scientific literature critically to facilitate novel research

· Proactively support the team by being a team player and foster strong cross-team and cross functional collaboration

• Biotechnology and Immunology Research
• I worked in the team where one of the major goals is to deliver right drug to right patients through development and implementation of robust biomarker and patient tailoring plans for multiple immunology assets in autoimmune therapeutic area
• My responsibility was development of in-vitro biomarker assays, their thorough characterization and validation of the assays before transferring to a CRO
• I organized meetings with external companies and also actively took part to solve potential issues and addressed crucial questions need to resolve
• I worked with immunoassays both bead based, and antibody based
• I was also involved working with ultrasensitive assays, such as single-plex,v-plex assays on MSD platform, bead based automated ELISA on Quanterix platform and digital PCR on modaplex platform
• I took part to develop a crucial biomarker platform which did not exist there before
• I contributed to ensure successful biomarker plan for certain indications
• Apart from working with blood/plasma/serum samples, I established a novel matrix – saliva to look for biomarker movements after compound treatment
• I successfully developed and characterized novel biomarker assays using saliva as matrix utilizing scientific knowledge and extensive literature search using a brand-new technology
• I worked closely with external collaborators, organized data files form them and presented the data in internal and external meetings which impacted team to make decision
• I managed one of the interns in the lab , mentored her with relevant scientific direction and trained her with her project related experiments
• Journal Papers
• Measurement of IL-21 in human serum and plasma using ultrasensitive MSD S-PLEX and Quanterix SiMoA methodologies” – JoshPoorbaugh, TanushreeSamanta, Stuart